SEC Filing Analysis: Artiva Biotherapeutics, Inc. (ARTV)

Executive Summary

• Trading Significance: Low
• Key Takeaway: The President and CEO, Fred Aslan, executed a small, pre-planned sale of common stock valued at approximately $19,122.
• Market Impact: The transaction is considered immaterial, representing just 0.024% of the company's market capitalization, and is unlikely to influence the market.

Company Information

Field	Value
Company	Artiva Biotherapeutics, Inc.
Ticker Symbol	ARTV
CIK	0001817241
Industry	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)

Insider Information

Field	Value
Name	Aslan Fred
CIK	0001909362
Title/Position	President and CEO
Relationship	Director, Officer

Transaction Details

Field	Value
Form Type	4
Transaction Date	2025-12-15
Transaction Code	S (Sale)
Security Type	Common Stock
Shares Involved	3,187
Price Per Share	$6.00
Total Value	$19,122
Shares Owned After	1,209,948
Ownership Type	Direct

Financial Impact Assessment

Transaction Materiality

Metric	Value
Transaction Value	$19,122
% of Market Cap	0.024%
Shares Transacted	3,187
% of Shares Outstanding	Not Available
Post-Transaction Ownership	1,209,948 shares
Materiality Assessment	Low

Impact Evaluation

• Market Cap Context: For a company with an $80 million market capitalization, this $19,122 transaction is minor and falls well below any threshold for significance.
• Ownership Concentration: The sale represents a negligible portion (~0.26%) of the insider's direct holdings, indicating no significant change in their conviction.

Market Impact Analysis

Stock Impact Prediction

• Direction: Neutral
• Reasoning: The transaction is small in absolute and relative terms. Furthermore, it was executed under a Rule 10b5-1 trading plan, which means it was pre-scheduled and not based on immediate, non-public information.

Volume & Sentiment

• Expected Volume Impact: Negligible. The transaction size is too small to impact trading volume.
• Sentiment Indicator: Neutral. This is a routine, pre-planned sale with no informational value to the market.

Additional Context

Transaction Notes

• Special Circumstances: The filing explicitly states the transaction was made pursuant to a Rule 10b5-1 trading plan adopted on July 23, 2024. This significantly reduces the trading significance as it indicates a pre-planned liquidity event rather than a reactive trade.